A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

NCT04401475 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

SUSPENDED

Status

644

Enrollment

INDUSTRY

Sponsor class

Stopped Edesa has made the decision to suspend this study solely for business reasons. The study stop is not related to any safety concerns of the product.

Conditions

COVID-19
ARDS

Interventions

BIOLOGICAL: SOC plus 15mg/kg EB05 IV
OTHER: SOC plus Placebo IV

Sponsor

Edesa Biotech Inc.

Collaborators

[object Object]